Briefing
Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial.
12-month DFS was 14.3% if MRD-positive vs 89.3% if MRD-negative. MRD positivity was associated with worse DFS in both arms (durvalumab HR 21.28, 95% CI 7.70-58.83; placebo HR 14.29, 95% CI 4.94-41.36). No MRD-positive patient in the durvalumab arm had a pathologic complete or major pathologic response. DFS trends favored durvalumab especially among MRD-negative patients (HR 0.56, 95% CI 0.26-1.20). KEAP1 and KMT2C mutations were associated with MRD-positive status in the durvalumab arm in this small exploratory analysis.
- n: 168 MRD-evaluable patients at a landmark a median of 6.9 weeks after surgery; 17 (10%) MRD-positive (10 durvalumab, 7 placebo)
- Assay: patient-specific tumor-informed assays (brand not named in the abstract)